Skip to main content
SpringerLink
Log in

Fehlreguliertes angeborenes Immunsystem

Neutrophile Dermatosen

  • Zertifizierte Fortbildung
  • Published:
hautnah dermatologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© Luise Erpenbeck

Abb. 2

© Luise Erpenbeck

Abb. 3

© Luise Erpenbeck

Abb. 4

© Luise Erpenbeck

Literatur

  1. Villarreal-Villarreal C et al. Sweet syndrome: a review and update. Actas dermo-sifiliograficas. 2016; 107: 369-78

  2. Agarwal A et al. Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab. JAMA Dermatol. 2016; 152: 842-4

  3. Reuss-Borst MA et al. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma. 1994; 15: 261-4

  4. Kawakami T et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol. 2004; 140: 570-4

  5. Patterson J et al. The vasculopathic reaction pattern. Weedon's Skin Pathology 4th ed Philadelphia, PA: Elsevier Churchill Livingstone. 2016.

  6. Croia C et al. Evaluation of neutrophil extracellular trap deregulated formation in pyoderma gangrenosum. Exp Dermatol. 2021; 30: 1340-4

  7. Bonnekoh H et al. Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation. Front Immunol. 2019; 10: 546

  8. Heath MS et al. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414

  9. Takahama H et al. Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome. Int J Dermatol. 2010; 49: 1079-80

  10. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535-56; quiz 557-60

  11. Su WP et al. Diagnostic criteria for Sweet's syndrome. Cutis. 1986; 37: 167-74

  12. Cohen PR et al. Sweet's syndrome and cancer. Clin Dermatol. 1993; 11: 149-57

  13. Raza S et al. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013; 42: 1516-22

  14. Sujobert P et al. Evidence of differentiation in myeloid malignancies associated neutrophilic dermatosis: a fluorescent in situ hybridization study of 14 patients. J Invest Dermatol. 2013; 133: 1111-4

  15. Aliper AM et al. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med. 2014; 3: 737-46

  16. Stucki A et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001; 97: 2121-9

  17. Cohen PR et al. Sweet's syndrome: a review of current treatment options. Am J Clin Dermatol. 2002; 3: 117-31

  18. Garcovich S et al. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017; 10: 1119-28

  19. Kluger N et al. Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret®) in a case of refractory Sweet's syndrome. Dermatology. 2011; 222: 123-7

  20. Marzano AV et al. A Comprehensive Review of Neutrophilic Diseases. Clin Rev Allergy Immunol. 2018; 54: 114-30

  21. Su WP et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004; 43: 790-800

  22. Maverakis E et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. JAMA Dermatol. 2018; 154: 461-6

  23. Marzano AV et al. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016; 175: 882-91

  24. Kontos AP et al. An open-label study of topical tacrolimus ointment 0.1% under occlusion for the treatment of pyoderma gangrenosum. Int J Dermatol. 2006; 45: 1383-5

  25. Ben Abdallah H et al. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J. 2019; 16: 511-21

  26. Herberger K et al. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges. 2019; 17: 32-41

  27. Kolios AG et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015; 173: 1216-23

  28. Szatkowski J et al. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015; 73: 843-8

  29. Sneddon IB et al. Subcorneal pustular dermatosis. Br J Dermatol 1956; 68: 385-94

  30. Watts PJ et al. Subcorneal Pustular Dermatosis: A Review of 30 Years of Progress. Am J Clin Dermatol 2016; 17: 653-71

  31. Sanchez N et al. Subcorneal pustular dermatosis: a variant of pustular psoriasis. Acta Derm Venereol Suppl (Stockh) 1979; 59: 147-51

  32. Ratnarathorn M et al. Subcorneal pustular dermatosis (Sneddon-Wilkinson disease) occurring in association with nodal marginal zone lymphoma: a case report. Dermatol Online J 2008; 14: 6

  33. Kretschmer L et al. Interruption of Sneddon-Wilkinson Subcorneal Pustulation with Infliximab. Case Rep Dermatol 2017; 9: 140-44

  34. Gooderham MJ et al. An update on generalized pustular psoriasis.Expert Rev Clin Immunol. 2019; 15: 907-19

  35. Booij MT et al. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011; 22: 86-9

  36. Onoufriadis A et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011; 89: 432-7

  37. Sugiura K et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013; 133: 2514-21

  38. Zhou J et al. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021; 47

  39. Mossner R et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018; 178: 740-8

  40. Bachelez H et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019; 380: 981-3

  41. Benjegerdes KE et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016; 6: 131-44

Download references

Author information

Authors and Affiliations

  1. Klinik für Hautkrankheiten, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland

    Steffen Schrenker &  Luise Erpenbeck

Authors
  1. Steffen Schrenker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luise Erpenbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luise Erpenbeck.

Ethics declarations

Die Autor*innen erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schrenker, S., Erpenbeck, L. Neutrophile Dermatosen. hautnah dermatologie 38, 44–50 (2022). https://doi.org/10.1007/s15012-021-6823-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-021-6823-5

Search

Navigation